SCHEMBL6237857

SCHEMBL6237857

O=C1C=Cc2ccc(O)cc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 4/20 1.00
CES1 P23141 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
BCHE P06276 1/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52
THRB P10828 1/20 0.52
PKM P14618 1/20 0.52
IDO1 P14902 1/20 0.52
HPGD P15428 1/20 0.52
ALOX15 P16050 1/20 0.52
PTPN1 P18031 1/20 0.52
ACHE P22303 1/20 0.52
RECQL P46063 1/20 0.52
KMT2A Q03164 1/20 0.52
HSD17B10 Q99714 1/20 0.52
PTPN22 Q9Y2R2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8232660 0.87 PTPRC (0.77) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL5401724 0.83 PTPRC (0.71) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL4955229 0.80 PTPRC (0.66) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL4648894 0.79 PTPRC (0.66) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL30412580 0.79 PTPRC (0.66) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL8204580 0.78 PTPRC (0.64) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL9817317 0.77 PTPRC (0.62) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL8597869 0.75 PTPRC (0.60) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL8147531 0.75 PTPRC (0.60) PTPRCCES1KDM4EMEN1ALDH1A1
SCHEMBL11028594 0.75 PTPRC (0.59) PTPRCCES1KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019113085-A1 ELECTROCHEMICAL DETECTION SYSTEMS AND COMPONENTS THEREOF Laxmi Therapeutic Devices, Inc. (US) 2019-06-13 WO disclosed
US-20190170739-A1 ELECTROCHEMICAL DETECTION SYSTEMS AND COMPONENTS THEREOF Laxmi Therapeutic Devices, Inc. 2019-06-06 US disclosed
US-6939896-B2 Naphthalenedione derivatives; treating autoimmune diseases and organ graft rejection ASTRAZENECA AB (SE) 2005-09-06 US disclosed
EP-1259231-B1 NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS ASTRAZENECA AB (SE) 2005-05-25 EP disclosed
US-20030119897-A1 Cd45 inhibitors ASTRAZENECA AB (SE) 2003-06-26 US disclosed
EP-1259231-A2 NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS AstraZeneca AB (SE) 2002-11-27 EP disclosed
WO-2001045681-A2 NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS ASTRAZENECA AB (SE) 2001-06-28 WO disclosed
EP-0439585-B1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS MAG GEORG MAYRHOFER & CO OHG (AT) 1997-10-29 EP disclosed
EP-0320227-B1 Method of preventing polymer-scale formation SHINETSU CHEMICAL CO (JP) 1994-09-07 EP disclosed
US-5196478-A Polystyrene, assays EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) 1993-03-23 US disclosed
EP-0439585-A1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS. EPIPHARM ALLERGIE SERVICE (AT) 1991-08-07 EP disclosed
WO-1991002768-A1 IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) 1991-03-07 WO disclosed
US-4933399-A COATING INSIDE OF VESSEL WITH A CATIONIC DYE, DRYING, COATING WITH AN ANIONIC OR AMPHOTERIC POLYMER OR A HYDROXYL-CONTAINING COMPOUND IN A SOLVENT SHIN-ETSU CHEMICAL CO., LTD. (JP) 1990-06-12 US disclosed
EP-0320227-A2 Method of preventing polymer-scale formation Shin-Etsu Chemical Co., Ltd. (JP) 1989-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119897-A1 Cd45 inhibitors PTPRC, CD2, HLA-C PTPRC 1/4885CES1 251/4885KDM4E 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.